Randomized clinical trials (RCTs) demonstrated the equal efficacy of urinary human chorionic\r\ngonadotropin (uhCG) and recombinant hCG (rhCG) products in in vitro fertilisation (IVF). However,\r\nlimitations inherent with RCTs necessitate the reinforcement of RCT results in real-life. We\r\nretrospectively analyzed pregnancies after treatment with rhCG and uhCG products (n = 391,\r\nand 96, resp.). We found that laboratory-verified pregnancy occurred more frequently in rhCG\r\npatients than in those on uhCG (43% versus 30%, P = 0.02). The association remains significant\r\n(P = 0.002) after its adjustment for clinical characteristics. The prevalence of laboratory-verified\r\npregnancies was higher with GnRH agonist use (P = 0.012) and BMI under 30 kg/m2 (P = 0.053)\r\nwhile decreased the age (P =0.014) and the number of previous failed attempts (P =0.08). Similar\r\n(but not significant) trends were observed with rates of pregnancy filled the 24th week. These\r\nresults reinforce RCTs supporting the notion that rhCG is more efficient as uhCG during IVF.
Loading....